Are the many new biologic drugs that launch each year bringing the clinical innovation that patients desperately need or the financial doom that healthcare benefit plan sponsors and their members cannot afford?  Or both?  What are biosimilar drugs and how can they help?  This podcast and its related series of articles in Health Watch helps actuaries better understand the potential clinical and financial impact that the coming wave of biosimilars could have on our healthcare system and how plan sponsors can best leverage it for their populations.